GlycoMark®, Inc. Announces Agreement with PrismHealthDx, Inc. to Expand Diabetes Test Panel with the GlycoMark Test
GlycoMark, Inc. and PrismHealthDx, Inc. have announced an agreement to offer the GlycoMark test to clinicians managing patients with diabetes. The GlycoMark test is the only FDA-cleared blood test for patients with diabetes that is specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring while fasting, postprandial, or both).
NEW YORK, Nov. 07, 2018 /PRNewswire-PRWeb/ -- GlycoMark, Inc. and PrismHealthDx, Inc. (PHDx) have announced an agreement to offer the GlycoMark® test to clinicians managing patients with diabetes. The GlycoMark test is the only FDA-cleared blood test for patients with diabetes that is specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring while fasting, postprandial, or both). As part of this agreement, PHDx is now promoting and offering the GlycoMark test to its network of physicians through its laboratory services organization.
Recent hyperglycemia (elevated blood sugar levels) and hyperglycemic excursions (blood sugar spikes) can go undetected with routine tests and put the patient at risk of diabetic complications including kidney disease, vision loss, amputation, heart attack and stroke. Nearly 40% of patients who are deemed to be in "good control" based on the A1C, a 3-month glucose average, may still have significant postprandial hyperglycemia or glycemic variability. Furthermore, a periodic blood glucose test is not always reliably timed or performed, and may yield inaccurate results.
"The GlycoMark test helps detect glycemic variability that is not evident with A1C," says Hiro Ishibashi, President of GlycoMark. "Our agreement with PHDx increases physician awareness and access to the GlycoMark test to so that patients at risk of significant diabetes complications can be more closely managed and treated."
"By integrating GlycoMark into our test menu, we are demonstrating our commitment to provide our clinicians, and their patients, access to important clinical technology focused on lowering cardiovascular risk and improving the care of patients with diabetes," says Jim Canfield, President and CEO of PHDx.
About GlycoMark, Inc.
GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East. The GlycoMark test is an FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at http://www.GlycoMark.com.
About PrismHealthDx, Inc. (PHDx)
PHDx is a precision medicine diagnostic laboratory and services company specializing in comprehensive biomarker testing to detect the onset of disease and serious medical conditions at their earliest and most treatable stage. PHDx provides a 'one-stop-shop' opportunity to integrate best-in-class laboratory and clinical medicine into practices, driving better clinical outcomes and helping to make an immediate difference in the lives of their patients. The PHDx management team has extensive experience in developing and commercializing novel assays and they are committed to advancing new diagnostic and disease management capabilities. PHDx works in partnership with academic leaders, industry leaders, and clinical providers.
GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.
SOURCE GlycoMark, Inc.
Share this article